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14 Tumor necrosis factor gene polymorphisms in cystic ﬁbrosis
patients
G.V. Shmarina, A.L. Pukhalsky, D.A. Pukhalskaya, L.V. Perederko, N.V. Petrova,
N.Y. Kashirskaya. Research Centre for Medical Genetics, Moscow, Russian
Federation
Tumor necrosis factor (TNF)-a and TNF-b, also known as lymphotoxin-a, exhibit a
broad spectrum of inﬂammatory and immunomodulatory activity. We hypothesized
that TNF genetic variations might affect inﬂammatory process and disease severity
in CF patients. Two biallelic polymorphisms have been studied: a G-to-A transi-
tion in position −308 in the promoter region of the TNF-a gene (G=TNF*A1,
A=TNF*A2) and a G-to-A transition at position +252 in the ﬁrst intron of the
TNF-b gene (G=TNF*B1, A=TNF*B2). 174 CF subjects (2−18 years) were
enrolled into the study. We did not ﬁnd any association between TNF genotypes
and CF lung disease progression. In the same time the carriers of TNF*A2 allele
more frequently had asthma and other atopic disorders as compared to patients
homozygous for TNF*A1 allele (14.9 vs 5.3% and 38.3 vs 25.7% respectively;
both p< 0.05). Accordingly, the subjects with TNF*A2 allele demonstrated a
signiﬁcant reduction in plasma ACTH levels (2.9 vs 5.4 pg/ml in patients with
both TNF*A1 alleles, p< 0.05). The carriers of TNF*B1 allele showed statistically
signiﬁcant association with atopic disorders (p< 0.05). However, there was no case
of tuberculosis or hepatitis in this group. In the same time 8.1% of patients
homozygous for TNF*B2 suffered from hepatitis and in 7.9% of TNF*B2/B2
carriers tuberculosis infection was documented (both p< 0.03). Besides, the subjects
with genotype TNF*B2/B2 demonstrated a signiﬁcant elevation of plasma TGF-b1
in comparison with TNF*B1 carriers (72.6 vs 32.4 pg/ml; p< 0.001). The results
suggest that TNF gene polymorphisms inﬂuence on course of CF disease and could
be a useful predictive marker for complication development.
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Background: Many studies show an association between genetic variation in the
human Angiotensin Converting Enzyme (ACE) gene and physical performance
in healthy individuals. One study in CF patients demonstrated an effect of ACE
polymorphisms on lung function, but the effect of these genetic variants on exercise
tolerance has never been investigated.
Aim: To investigate the effect of the ACE I/D polymorphism on lung function and
physical performance in children with CF.
Methods: All children with CF 4 years or older undergo routine multidisciplinary
examination regardless of their health status. This examination includes lung
function and symptom limited exercise testing. The ACE I/D polymorphism was
determined in ~90% of our paediatric CF population. Patients with a mild or
unknown CFTR genotype were excluded from this study.
Results: 172 patients were included in the study. Lung function was signiﬁcantly
higher in patients with the ACE II genotype compared with the ID and DD genotype
(83% vs 76% of predicted, p = 0.03). Furthermore, patients with the II genotype
tended to have a higher VO2, VO2/kg and load at ventilatory anaerobic threshold
(calculated as percentage of predicted maximum) than the ID and DD genotype.
Finally, our data indicated higher muscle force of the leg extensors in patients with
the II genotype. These data are in accordance with previously performed studies in
healthy individuals.
Conclusion: Polymorphisms in the ACE gene are associated with lung function and
physical performance in children with CF. These ﬁndings may have implications
for physical training strategies.
Supported by: The Netherlands Organization for Health Research and Development
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Aim: The objective was to correlate antioxidant markers, GST, glutathione, vitamins
A, E, C with time and severity of Pseudomonas aeruginosa lung infection in cystic
ﬁbrosis children.
Methods: Thirty six CF children (18 girls, 18 boys 10 yrs median age) and
9 controls (3 girls, 6 boys, 8 yrs median age), GSTM1, P1, T1 genotype, total
GST activity (spectrophotometry), erythrocyte glutathione and plasma vitamins A,
E, C (HPLC) were studied.
Results: No difference between controls and CF children total GST activity. (1) GST
activity is signiﬁcantly correlated with the CF clinical status, higher in good status
vs lower in severe one. Twenty four (11 girls, 13 boys) over the 36 CF had a
ﬁrst infection with P. aeruginosa (14 under 5 yrs (6 girls, 8 boys) and 10 over
5 yrs (5 girls, 5 boys), and 12 over these 24 (6 of each sex) kept the colonisation
at time of blood collection. (2) In presence of infection, a signiﬁcant lower total
GST activity is observed. (3) GSTP1 AG is more frequent in infected CF patients
compared to non infected one’s (38% vs. 16%) whereas P1 AA is more represented
in non infected CF children (75% vs. 46%). Increase M1−0/0 frequency was related
with worse clinical status and is prevalent in early infection (3/4 girls vs. 1/3 boys
under 5 yrs), T1−0/0 is found only in infected CF children.
Conclusion: Our data suggests an elevated early risk for P. aeruginosa severe
infection related to the presence of GSTM1-P1 polymorphisms and a signiﬁcant
decrease of total GST activity.
Supported by: “Association Mucoviscidose ABCF prote´ines”.
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Seventeen years after the discovery of the CFTR gene, more than 1500 changes
and polymorphisms have been reported. The current strategies of CFTR analysis
which include techniques such as DHPLC for the screening of point mutations,
and quantitative PCR technologies such as QMPSF for the screening of large
rearrangements, make that less and less changes of CFTR gene remain unidentiﬁed.
In our population from Brittany, France, less than 1% of the chromosomes have
still to be characterized.
We report the case of a family, in which the patient carried the F508del mutation,
and a second mutation which had not been identiﬁed after complete analysis of
the gene by DHPLC and QMPSF. The couple, despite the possibility of a prenatal
diagnosis, had given birth to another child. Analysis of microsatellite markers in
the whole family showed that the CF patient and his young sister received the
same parental chromosomes, thus suggesting the de novo appearance of the second
mutation. In order to identify the molecular defect in this patient, we undertook a
qualitative analysis of cDNA CFTR from a lymphocyte cell line. Four couples of
primers were designed to amplify the whole coding sequence of the cDNA from this
patient compared to a control. Ampliﬁcation of exons 7 to 13 normally gives rise
to two transcripts, a normal one (exon 9+) and another with an in frame deletion of
exon 9. In our patient, 4 different transcripts were obtained. Sequencing allows the
characterization of the molecular defect, which corresponds to a partial duplication
of exons 7 and 8.
Analysis of CFTR transcripts is thus feasible from lymphocytes, and could be used
when the molecular defect remains uncharacterized after complete scanning of the
gene by conventional techniques.
